Patent ID: 8110687

Claim:
A compound of formula (I-A): or a pharmaceutically acceptable salt thereof; wherein: G 1 is —O—; G 2 is —C(O)—NH or —NH—C(O); Ring A is Ring B has the formula: X is CH; X 1 and X 2 are each CH; Q is —C(R 10 )(R 11 )—C(R 10 )(R 11 )— or —C(R 11 )═C(R 11 )—; R 9b is hydrogen; R 10 is hydrogen; R 11 is hydrogen; R b is selected from the group consisting of Ring D, —R 1b , —R 2b , -T 1 —R 1b , -T 1 —R 2b , —V 1 -T 1 —R 1b , —V 1 -T 1 —R 2b ; wherein Ring D is selected from the group consisting of imidazolyl, oxazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, oxadiazolyl, imidazolinyl, oxazolinyl, piperazinyl, pyridyl, and pyrimidinyl; each substitutable unsaturated ring carbon atom in Ring D is unsubstituted or is substituted with —R d ; each substitutable ring nitrogen atom in Ring D is unsubstituted or is substituted with C 1-4 aliphatic; each R d independently is C 1-4 aliphatic optionally substituted with halo, —OH, pyrrolyl, or piperazinyl, —R 1d , —R 2d , -T 3 —R 1d , or -T 3 —R 2d ; T 3 is a C 1-4 alkylene chain; each R 1d independently is piperazinyl optionally substituted with C 1-4 aliphatic; each R 2d independently is —N (R 4 ) 2 , —CO 2 R 5 or —C(O)N(R 4 ) 2 ; T 1 is a C 1-6 alkylene chain, wherein the alkylene chain optionally is interrupted by —N(R 4 )C(O)—; V 1 is —N(R 4 )—, —N(R 4 )C(O)—, —N(R 4 )CO 2 —, or —C(═NR 4 )—N(R 4 ); R 1b is phenyl, pyrrolidinyl, piperazinyl, or morpholinyl, optionally substituted with C 1-4 aliphatic or —OCH 3 ; each R 2b independently is —OR 5 , —N(R 4 ) 2 , —NR 4 C(O)R 5 , —NR 4 C(O)N(R 4 ) 2 , —NR 4 CO 2 R 6 , —N(R 4 )SO 2 R 6 , —C(O)N(R 4 ) 2 or —C(═NR 4 )—N(R 4 ) 2 ; Ring C is phenyl; Ring C is substituted on its substitutable ring carbon atoms with 0-2 R c and 0-2 R 8c ; each R c independently is halo, —NO 2 , —CN, —C(R 5 )═C(R 5 ) 2 , —OR 5 , —SR 6 , —SO 2 R 6 , —SO 2 N(R 4 ) 2 , —N(R 4 ) 2 , —C(O)R 5 , or phenyl, pyrazolyl, pyrrolidinyl, or tetrazolyl; each R 8c independently is selected from the group consisting of C 1-4 aliphatic, C 1-4 fluoroaliphatic, —O(C 1-4 aliphatic), —O(C 1-4 fluoroaliphatic), and halo; each R 4 independently is hydrogen or an aliphatic optionally substituted with —N(CH 3 ) 2 or —OR 5 ; or two R 4 on the same nitrogen atom, taken together with the nitrogen atom, form a piperazinyl, pyrrolidinyl, or morpholinyl ring, optionally substituted with C 1-4 aliphatic; each R 5 independently is hydrogen, phenyl, or an aliphatic optionally substituted with halo —OH, —N(CH 3 ) 2 or pyrrolidinyl; each R 6 independently is an aliphatic; n is 0 or 1; and m is 0.